"Designing Growth Strategies is in our DNA"

Liver Cancer Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Therapy Type (Targeted Drug Therapy, Immunotherapy, and Chemotherapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027

Last Updated: July 01, 2024 | Format: PDF | Report ID: FBI104657



Play Audio Listen to Audio Version

The global liver cancer therapeutics market size was valued at USD 1,730.9 million in 2019 and is projected to grow from USD 2,037.5 million in 2020 to USD 7,382.1 million by 2027, exhibiting a CAGR of 20.2% during 2020-2027 period. 

Based on our analysis, the global market will exhibit a stellar growth of 19.0% in 2020. The global impact of COVID-19 has been unprecedented and staggering, with liver cancer therapeutics witnessing a positive demand shock across all regions amid the pandemic. The sudden rise in CAGR is attributable to this market’s demand and growth, returning to pre-pandemic levels once the pandemic is over. According to an evaluated pharma report, the oncology area represented the largest proportion of around 40% of the drug pipeline in 2019 and 20% of the pharmaceutical industry revenue. A few numbers of drugs have been approved for the treatment of hepatocellular carcinoma, which accounts for 90% of liver cancer. According to Globocan, there are approximately 1.2 million patients diagnosed with cases of liver cancer annually worldwide. This has led to an increase in the sales of drugs. Additionally, a higher percentage of the medications' effectiveness and potentiality are responsible for the rise in company sales globally.

Robust research and development against the deadly disease has emerged in the launch of novel drugs. For example, in May 2020, Roche received U.S Food and Drug Administration (FDA) approval for the launch of immunotherapy Tecentriq in combination with Avastin indicated against the treatment of liver cancer. These drugs are used to lower the cancer cells in the body and lower the symptoms. Therefore, boosting the liver cancer drugs market growth during the forecast period.

COVID-19 Pandemic to Have a Positive Impact on Product Sales

The COVID-19 pandemic has had a positive impact on the global liver cancer therapeutics market due to a surge in the sales of the products concerning the COVID-19 emergency. The pharmaceutical companies amid the pandemic have significantly focused on maintaining the balance between supply and demand thus keeping their sales intact. Health organizations have issued necessary guidelines and recommendations for the management of hepatocellular carcinoma patients in the COVID-19 era, leading to demand in the therapeutic drug supply. For instance, the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), National Institute of Health and Care Excellence (NICE), etc., have proposed guidelines. Moreover, several research studies have confirmed that patients with HCC are at higher risk of contracting the infection. Therefore, these patients were considered in the emergency category during the pandemic.


Request a Free sample to learn more about this report.

Robust R&D by Companies to Improve Market Potential

The fundamental aim of cancer treatment is to cure the disease through therapeutic drugs, prolong patient survival, and improve life quality. Immune cells play a crucial role in tumor progression, and therefore companies have focused on R&D of immunotherapy and targeted drug therapy to achieve a faster prognosis. For example, in January 2020, Sirnaomics and Innovent Biologics Inc. entered into a collaboration agreement to conduct clinical studies on RNAi drug candidate STP705 and drug Tyvyt as a combination in treatment against advanced liver cancer such as HCC. Therefore, with the help of strategic collaborations among the industry players, liver cancer research and development has reached new heights, subsequently contributing to an increase in its market size.


Increasing Prevalence of Liver Cancer to Propel Product Demand

Globally, increase in the incidence of liver cancer has marked as the second leading cause of death after cardiovascular disorders. Environmental factors, alcohol consumption, smoking, and increasing urbanization are mainly responsible for its prevalence. For instance, according to the World Cancer Research Fund, in 2018, there were around 840 000 new cases of liver cancer. Thus, a higher prevalence and demand for effective drugs is anticipated to drive the market growth during the forecast period.

Robust Drug Pipeline to Aid Growth Opportunities

Cancer research and development to provide advanced patient care is accelerating year by year. Innovative experiments leading to combination therapy with new or existing drug molecules have shown to rise in the pipeline candidates for liver cancer treatment. Also, strong backing from government and international healthcare organizations for R&D funding is likely to contribute to the liver cancer market opportunities. This coupled with the growing preference for biosimilars entering the market, is projected to augment the market growth.


Adverse Effects of Drugs and Stringent Regulations to Restrict Market Growth

Treating cancer cells with a high dose of the drugs leads to the destruction of tumor cells and damages the normal cells of the body to a greater extent. This results in various side effects such as gastrointestinal disorders, hair loss, fatigue, skin disorders, etc. in many patients. Therefore, these adverse events pertaining to the oncology drugs are negatively influencing the growth of the global market for liver cancer drugs.  Additionally, strict regulations regarding clinical studies by the regulatory bodies are also another factor causing hindrance in market growth.


By Therapy Type Analysis

To know how our report can help streamline your business, Speak to Analyst

Increased Sales of Products for Targeted Drug Therapy to Foster Growth

Based on the therapy type, the market segment includes targeted drug therapy, chemotherapy, and immunotherapy. The targeted drug therapy segment accounts for the majority of the market share in 2019. Targeted therapy is focused on precisely killing the target tumor cells and eliminating side effects on the normal cells. This factor leads to the more outstanding recommendation of drugs by hospitals and oncology physicians through prescription. Moreover, the growing number of pipeline candidates coupled with product approvals is anticipated to fuel the segment growth during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

On the other hand, the immunotherapy segment is expected to emerge as the fastest-growing segment during the forecast period due to innovative drugs for liver cancer treatment. For example, in June 2020, the U.S FDA approved Roche’s immunotherapy regimen that includes a combination of Tecentriq and Avastin to treat liver cancer patients.

By Distribution Channel Analysis

Growing Prescription of Medications at Hospitals to Contribute Growth

In terms of the distribution channel, the market for liver cancer therapeutics is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment holds the lion’s share globally due to increased patient visits and sales of prescription-based drugs for treatment against liver cancer disorders, mainly hepatocellular carcinoma. Also, the rise in the patient preference to buy products from nearby pharmacies on a regular basis is responsible for the growth of this segment. The online pharmacy segment is expected to witness lucrative CAGR over the forecast period due to the penetration of online pharmacies in emerging countries and other developing countries.


North America Liver Cancer Therapeutics Market 2016-2027 (USD Million)

To get more information on the regional analysis of this market, Request a Free sample

The market size in North America stood at USD 1,106.3 million in 2019. The dominance of this region is attributable to the rising incidence rates of liver cancer among the U.S population. Another major factor contributing to the growth of the region is the presence of major players coupled with the launch of products. Europe holds the second position in the market owing to its investments in R&D for the development of therapeutically effective drugs. This, along with higher sales of targeted drug therapy products, is expected to drive the growth during the forecast period. Moreover, Asia Pacific is anticipated to witness a high CAGR due to the growing number of clinical studies about liver disease including cancer and the region's increased geriatric population. On the other hand, Latin America, and Middle East & Africa are likely to witness comparatively slower growth due to slower adoption of high-cost liver cancer drugs coupled with lack of product approvals in most under-developed countries.


Significant R&D Investments by Key Players to Improve Business Outcome

The market is consolidated owing to the presence of limited market players with a focus on liver cancer therapeutics. Bayer AG and Eisai Inc. have a larger market share. The industry players' dominance is attributable to strong sales of oncology drugs for liver cancer coupled with strategic investments and collaborations to proliferate the product portfolio. Additionally, the emergence of new players during the forecast period and multiple product approvals is anticipated to broaden the scope of the global market. For instance, in January 2020, AstraZeneca received Orphan Drug Designation (ODD) for its Imfinzi and tremelimumab drugs indicated against HCC treatment.


  • Bayer HealthCare Pharmaceuticals Inc. (Leverkusen, Germany)

  • Bristol-Myers & Squibb Company (New York, United States)

  • Pfizer Inc. (New York, United States)

  • Exelixis, Inc. (California, United States)

  • Merck Sharp & Dohme Corp. (New jersey, United States)

  • Eisai Inc. (Tokyo, Japan)

  • Eli Lilly and Company (Indiana, United States)

  • F. Hoffmann-La Roche Ltd (Basel, Switzerland)

  • Other Players


  • January 2021- F. Hoffmann-La Roche Ltd., presented an updated overall survival data from the Phase III IMbrave150 study evaluating increased survival rate of liver cancer patients by treating them with a combination of Tecentriq and Avastin

  • November 2020- F. Hoffmann-La Roche Ltd., announced the European Commission (EU) approval of Tecentriq in combination with Avastin for the treatment of liver cancer with an aim to increase product line as well as enhance the brand presence in the European countries.

  • May 2020- The U.S. FDA approved atezolizumab with a combination with bevacizumab for the initial treatment of liver cancer.


An Infographic Representation of Liver Cancer Therapeutics Market

To get information on various segments, share your queries with us

The global liver cancer therapeutics market research report provides a detailed analysis of the market. It focuses on key aspects such as leading companies, product types, and leading applications of the product. Besides this, the report offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the developed market in recent years.

Report Scope & Segmentation



Study Period


Base Year


Forecast Period


Historical Period



  Value (USD Million)




By Therapy Type

  • Targeted Drug Therapy

  • Immunotherapy

  • Chemotherapy

By Distribution Channel

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

By Geography

  • North America (Therapy Type; Distribution Channel; and Region)

    • USA (By Therapy Type)

    • Canada (By Therapy Type)

  • Europe (Therapy Type; Distribution Channel; and Region)

  • UK (By Therapy Type)

  • Germany (By Therapy Type)

  • France (By Therapy Type)

  • Italy (By Therapy Type)

  • Spain (By Therapy Type)

  • Scandinavia (By Therapy Type)

  • Rest of Europe (By Therapy Type)

  • Asia Pacific (Therapy Type; Distribution Channel; and Region)

    • Japan (By Therapy Type)

    • China (By Therapy Type)

    • India (By Therapy Type)

    • Australia (By Therapy Type)

    • Southeast Asia (By Therapy Type)

    • Rest of Asia Pacific (By Therapy Type)

  • Latin America (Therapy Type; Distribution Channel; and Region)

    • Brazil (By Therapy Type)

    • Mexico (By Therapy Type)

    • Rest of Latin America (By Therapy Type)

  • Middle East & Africa (Therapy Type; Distribution Channel; and Region)

    • GCC (By Therapy Type)

    • South Africa (By Therapy Type)

    • Rest of MEA (By Therapy Type)

Frequently Asked Questions

Fortune Business Insights says that the global market size for liver cancer therapeutics was USD 1,730.9 million in 2019 and is projected to reach USD 7,382.1 million by 2027.

In 2019, the North American market size stood at USD 1,106.3 million.

Growing at a CAGR of 20.2%, the market will exhibit strong growth in the forecast period (2020-2027).

The targeted drug therapy segment is expected to be the leading segment in this market during the forecast period.

The increasing prevalence of hepatocellular carcinoma globally and the introduction of advanced products by market players are major factors driving the growth of the market.

Bayer AG, Eisai Inc., and F. Hoffmann-La Roche Ltd are major players in the global market.

North America dominated the market share in 2019.

The increased burden of under-diagnosed liver diseases and the demand for effective products in emerging nations are expected to drive the adoption in the global market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • 2019-2032
    (In Process)
  • 2023
    (In Process)

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients


Related Reports

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.